Mira Pharmaceuticals Inc. (MIRA)
NASDAQ
Closed
Aug 25, 2026
Day's Range
0.768352 wk Range
0.6000Overview - MIRA - Mira Pharmaceuticals Inc.
Key Statistics
Valuation
Enterprise Value
25.00M
P/E (Trailing)
‪-0.59‬
P/E (Forward)
‪-1.92‬
PEG Ratio
‪0.0081‬
Price / Book
‪4.06‬
EV / EBITDA
‪-2.39‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-129.54%‬
Return on Equity
‪-217.12%‬
Ownership
Shares Outstanding
42.02M
Float
35.02M
Short % of Shares Outstanding
‪0.53%‬
Held by Insiders
‪30.58%‬
Held by Institutions
‪5.42%‬
Price stats
Beta
‪1.55‬
50-Day Avg
‪0.8618‬
200-Day Avg
‪1.14‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - MIRA - Mira Pharmaceuticals Inc.
Peers - MIRA - Mira Pharmaceuticals Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on NASDAQ.
- MIRANASDAQMira Pharmaceuticals Inc.33.11MMarket Cap-73.75%52-week change-0.59P/E (Trailing)‪0.00%‬Profit Margin
- AZNNASDAQAstraZeneca PLC American Depositary Shares258.54BMarket Cap+4.43%52-week change24.88P/E (Trailing)‪17.02%‬Profit Margin
- AMGNNASDAQAmgen Inc.239.95BMarket Cap+34.76%52-week change27.32P/E (Trailing)‪22.95%‬Profit Margin
- GILDNASDAQGilead Sciences Inc.181.95BMarket Cap+22.21%52-week change17.87P/E (Trailing)‪-10.63%‬Profit Margin
- SNYNASDAQSanofi American Depositary Receipt109.47BMarket Cap-9.72%52-week change24.26P/E (Trailing)‪8.09%‬Profit Margin
- ROPNASDAQRoper Technologies Inc.41.09BMarket Cap-26.22%52-week change17.15P/E (Trailing)‪30.24%‬Profit Margin
- BIIBNASDAQBiogen Inc.32.22BMarket Cap+37.32%52-week change38.44P/E (Trailing)‪8.32%‬Profit Margin
Profile Summary - MIRA - Mira Pharmaceuticals Inc.
About
Mira Pharmaceuticals Inc. operates in the biotechnology industry, focusing on the research and development of novel therapeutics. The company is dedicated to advancing pharmaceuticals that address unmet medical needs, primarily targeting neurological and neuropsychiatric disorders. Through innovative drug development…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
